-
2
-
-
84872620069
-
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
-
Parisi, R.; Symmons, D.P.; Griffiths, C.E.; Ashcroft, D.M. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J. Invest. Dermatol. 2013, 133, 377-385.
-
(2013)
J. Invest. Dermatol
, vol.133
, pp. 377-385
-
-
Parisi, R.1
Symmons, D.P.2
Griffiths, C.E.3
Ashcroft, D.M.4
-
3
-
-
0038104272
-
Prevalence of joint disease in patients with psoriasis: Implications for therapy
-
Zachariae, H. Prevalence of joint disease in patients with psoriasis: Implications for therapy. Am. J. Clin. Dermatol. 2003, 4, 441-447.
-
(2003)
Am. J. Clin. Dermatol
, vol.4
, pp. 441-447
-
-
Zachariae, H.1
-
4
-
-
70349775684
-
The prevalence of psoriatic arthritis in people with psoriasis
-
Ibrahim, G.; Waxman, R.; Helliwell, P.S. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis. Rheum. 2009, 61, 1373-1378.
-
(2009)
Arthritis. Rheum
, vol.61
, pp. 1373-1378
-
-
Ibrahim, G.1
Waxman, R.2
Helliwell, P.S.3
-
5
-
-
42149087160
-
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells
-
Lowes, M.A; Kikuchi, T.; Fuentes-Duculan, J.; Cardinale, I.; Zaba, L.C.; Haider, A.S.; Bowman, E.P.; Krueger, J.G. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 2008, 128, 1207-1211.
-
(2008)
J. Invest. Dermatol
, vol.128
, pp. 1207-1211
-
-
Lowes, M.A.1
Kikuchi, T.2
Fuentes-Duculan, J.3
Cardinale, I.4
Zaba, L.C.5
Haider, A.S.6
Bowman, E.P.7
Krueger, J.G.8
-
6
-
-
84255162807
-
The multitasking organ: Recent insights into skin immune function
-
Di Meglio, P.; Perera, G.K.; Nestle, F.O. The multitasking organ: Recent insights into skin immune function. Immunity 2011, 35, 857-869.
-
(2011)
Immunity
, vol.35
, pp. 857-869
-
-
Di Meglio, P.1
Perera, G.K.2
Nestle, F.O.3
-
7
-
-
33750524246
-
Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review and economic evaluation
-
Woolacott, N.; Bravo, V.Y.; Hawkins, N.; Kainth, A.; Khadjesari, Z.; Misso, K.; Light, K.; Asseburg, C.; Palmer, S.; Claxton, K.; Bruce, I.; Sculpher, M.; Riemsma, R. Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review and economic evaluation. Health Technol. Assess. 2006, 10, 1-239.
-
(2006)
Health Technol. Assess
, vol.10
, pp. 1-239
-
-
Woolacott, N.1
Bravo, V.Y.2
Hawkins, N.3
Kainth, A.4
Khadjesari, Z.5
Misso, K.6
Light, K.7
Asseburg, C.8
Palmer, S.9
Claxton, K.10
Bruce, I.11
Sculpher, M.12
Riemsma, R.13
-
8
-
-
14244268696
-
Psoriatic arthritis treatment: Biological response modifiers
-
Mease, P.J.; Antoni, C.E. Psoriatic arthritis treatment: Biological response modifiers. Ann. Rheum Dis. 2005, 64(Suppl. 2), 78-82.
-
(2005)
Ann. Rheum Dis
, vol.64
, Issue.2 SUPPL.
, pp. 78-82
-
-
Mease, P.J.1
Antoni, C.E.2
-
9
-
-
84865605441
-
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
-
Gottlieb, A.B.; Langley, R.G.; Strober, B.E.; Papp, K.A.; Klekotka, P.; Creamer, K.; Thompson, E.H.; Hooper, M.; Kricorian, G. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br. J. Dermatol. 2012, 167, 649-657.
-
(2012)
Br. J. Dermatol
, vol.167
, pp. 649-657
-
-
Gottlieb, A.B.1
Langley, R.G.2
Strober, B.E.3
Papp, K.A.4
Klekotka, P.5
Creamer, K.6
Thompson, E.H.7
Hooper, M.8
Kricorian, G.9
-
10
-
-
84870234325
-
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: Results from PROGRESS, an open-label Phase IIIB trial
-
Strober, B.E.; Sobell, J.M.; Duffin, K.C.; Bao, Y.; Guérin, A.; Yang, H.; Goldblum, O.; Okun, M.M.; Mulani, P.M. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: Results from PROGRESS, an open-label Phase IIIB trial. Br. J. Dermatol. 2012, 167, 1374-1381.
-
(2012)
Br. J. Dermatol
, vol.167
, pp. 1374-1381
-
-
Strober, B.E.1
Sobell, J.M.2
Duffin, K.C.3
Bao, Y.4
Guérin, A.5
Yang, H.6
Goldblum, O.7
Okun, M.M.8
Mulani, P.M.9
-
11
-
-
84863336589
-
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: Results of a phase II randomized, placebo-controlled trial with a re-treatment extension
-
Reich, K.; Ortonne, J.P.; Gottlieb, A.B.; Terpstra, I.J.; Coteur, G.; Tasset, C.; Mease, P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: Results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br. J. Dermatol. 2012, 167, 180-190.
-
(2012)
Br. J. Dermatol
, vol.167
, pp. 180-190
-
-
Reich, K.1
Ortonne, J.P.2
Gottlieb, A.B.3
Terpstra, I.J.4
Coteur, G.5
Tasset, C.6
Mease, P.7
-
12
-
-
36749070996
-
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents
-
Nesbitt, A.; Fossati, G.; Bergin, M.; Stephens, P.; Stephens, S.; Foulkes, R.; Brown, D.; Robinson, M.; Bourne, T. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm. Bowel Dis. 2007, 13, 1323-1332.
-
(2007)
Inflamm. Bowel Dis
, vol.13
, pp. 1323-1332
-
-
Nesbitt, A.1
Fossati, G.2
Bergin, M.3
Stephens, P.4
Stephens, S.5
Foulkes, R.6
Brown, D.7
Robinson, M.8
Bourne, T.9
-
13
-
-
84866552180
-
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis
-
Kanakaraj, P.; Puffer, B.A.; Yao, X.T.; Kankanala, S.; Boyd, E.; Shah, R.R.; Wang, G.; Patel, D.; Krishnamurthy, R.; Kaithamana, S.; et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012, 4, 600-613.
-
(2012)
MAbs
, vol.4
, pp. 600-613
-
-
Kanakaraj, P.1
Puffer, B.A.2
Yao, X.T.3
Kankanala, S.4
Boyd, E.5
Shah, R.R.6
Wang, G.7
Patel, D.8
Krishnamurthy, R.9
Kaithamana, S.10
-
14
-
-
79954600126
-
Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis
-
Jung, K.; Lee, D.; Lim, H.S.; Lee, S.I.; Kim, Y.J.; Lee, G.M.; Kim, S.C.; Koh, G.Y. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J. Biol. Chem. 2011, 286, 14410-14418.
-
(2011)
J. Biol. Chem
, vol.286
, pp. 14410-14418
-
-
Jung, K.1
Lee, D.2
Lim, H.S.3
Lee, S.I.4
Kim, Y.J.5
Lee, G.M.6
Kim, S.C.7
Koh, G.Y.8
-
15
-
-
84555190295
-
Investigational VEGF antagonists for psoriasis
-
Crawshaw, A.A.; Griffiths, C.E.; Young, H.S. Investigational VEGF antagonists for psoriasis. Expert Opin. Investig. Drugs 2012, 21, 33-43.
-
(2012)
Expert Opin. Investig. Drugs
, vol.21
, pp. 33-43
-
-
Crawshaw, A.A.1
Griffiths, C.E.2
Young, H.S.3
-
16
-
-
33846906224
-
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
-
Zheng, Y.; Danilenko, D.M.; Valdez, P.; Kasman, I.; Eastham-Anderson, J.; Wu, J.; Ouyang, W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445, 648-651.
-
(2007)
Nature
, vol.445
, pp. 648-651
-
-
Zheng, Y.1
Danilenko, D.M.2
Valdez, P.3
Kasman, I.4
Eastham-Anderson, J.5
Wu, J.6
Ouyang, W.7
-
17
-
-
74249094930
-
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
-
ACCEPT Study group
-
Griffiths, C.E.; Strober, B.E.; van de Kerkhof, P.; Ho, V.; Fidelus-Gort, R.; Yeilding, N.; Guzzo, C.; Xia, Y.; Zhou, B.; Li, S.; et al. ACCEPT Study group. comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl. J. Med. 2010, 362, 118-128.
-
(2010)
N Engl. J. Med
, vol.362
, pp. 118-128
-
-
Griffiths, C.E.1
Strober, B.E.2
van de Kerkhof, P.3
Ho, V.4
Fidelus-Gort, R.5
Yeilding, N.6
Guzzo, C.7
Xia, Y.8
Zhou, B.9
Li, S.10
-
18
-
-
84858633545
-
PHOENIX 1, PHOENIX 2, and ACCEPT investigators. An update on the long-term safety experience of ustekinumab: Results from the psoriasis clinical development program with up to four years of follow-up
-
Reich, K.; Papp, K.A.; Griffiths, C.E.; Szapary, P.O.; Yeilding, N.; Wasfi, Y.; Ott, E.; Hsu, M.C.; Lebwohl, M.; Gordon, K.B. PHOENIX 1, PHOENIX 2, and ACCEPT investigators. An update on the long-term safety experience of ustekinumab: Results from the psoriasis clinical development program with up to four years of follow-up. J. Drugs Dermatol. 2012, 11, 300-312.
-
(2012)
J. Drugs Dermatol
, vol.11
, pp. 300-312
-
-
Reich, K.1
Papp, K.A.2
Griffiths, C.E.3
Szapary, P.O.4
Yeilding, N.5
Wasfi, Y.6
Ott, E.7
Hsu, M.C.8
Lebwohl, M.9
Gordon, K.B.10
-
19
-
-
84859017988
-
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
-
Papp, K.A.; Leonardi, C.; Menter, A.; Ortonne, J.P.; Krueger, J.G.; Kricorian, G.; Aras, G.; Li, J.; Russell, C.B.; Thompson, E.H.; Baumgartner, S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl. J. Med. 2012, 366, 1181-1189.
-
(2012)
N Engl. J. Med
, vol.366
, pp. 1181-1189
-
-
Papp, K.A.1
Leonardi, C.2
Menter, A.3
Ortonne, J.P.4
Krueger, J.G.5
Kricorian, G.6
Aras, G.7
Li, J.8
Russell, C.B.9
Thompson, E.H.10
Baumgartner, S.11
-
20
-
-
84859073115
-
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis
-
Leonardi, C.; Matheson, R.; Zachariae, C.; Cameron, G.; Li, L.; Edson-Heredia, E.; Braun, D.; Banerjee, S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl. J. Med. 2012, 366, 1190-1199.
-
(2012)
N Engl. J. Med
, vol.366
, pp. 1190-1199
-
-
Leonardi, C.1
Matheson, R.2
Zachariae, C.3
Cameron, G.4
Li, L.5
Edson-Heredia, E.6
Braun, D.7
Banerjee, S.8
-
21
-
-
84865592373
-
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study
-
Papp, K.A.; Menter, A.; Strober, B.; Langley, R.G.; Buonanno, M.; Wolk, R.; Gupta, P.; Krishnaswami, S.; Tan, H.; Harness, J.A. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 2012, 167, 668-677.
-
(2012)
Br. J. Dermatol
, vol.167
, pp. 668-677
-
-
Papp, K.A.1
Menter, A.2
Strober, B.3
Langley, R.G.4
Buonanno, M.5
Wolk, R.6
Gupta, P.7
Krishnaswami, S.8
Tan, H.9
Harness, J.A.10
-
22
-
-
51349152055
-
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis
-
Skvara, H.; Dawid, M.; Kleyn, E.; Wolff, B.; Meingassner, J.G.; Knight, H.; Dumortier, T.; Kopp, T.; Fallahi, N.; Stary, G.; et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J. Clin. Invest. 2008, 118, 3151-3159.
-
(2008)
J. Clin. Invest
, vol.118
, pp. 3151-3159
-
-
Skvara, H.1
Dawid, M.2
Kleyn, E.3
Wolff, B.4
Meingassner, J.G.5
Knight, H.6
Dumortier, T.7
Kopp, T.8
Fallahi, N.9
Stary, G.10
-
23
-
-
77249116286
-
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
-
Schafer, P.H.; Parton, A.; Gandhi, A.K.; Capone, L.; Adams, M.; Wu, L.; Bartlett, J.B.; Loveland, M.A.; Gilhar, A.; Cheung, Y.F.; et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br. J. Pharmacol. 2010, 159, 842-855.
-
(2010)
Br. J. Pharmacol
, vol.159
, pp. 842-855
-
-
Schafer, P.H.1
Parton, A.2
Gandhi, A.K.3
Capone, L.4
Adams, M.5
Wu, L.6
Bartlett, J.B.7
Loveland, M.A.8
Gilhar, A.9
Cheung, Y.F.10
-
24
-
-
84865373941
-
Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial
-
Papp, K.; Cather, J.C.; Rosoph, L.; Sofen, H.; Langley, R.G.; Matheson, R.T.; Hu, C.; Day, R.M. Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial. Lancet 2012, 380, 738-746.
-
(2012)
Lancet
, vol.380
, pp. 738-746
-
-
Papp, K.1
Cather, J.C.2
Rosoph, L.3
Sofen, H.4
Langley, R.G.5
Matheson, R.T.6
Hu, C.7
Day, R.M.8
-
25
-
-
84856215488
-
Low-dose rituximab is effective in pemphigus
-
Horváth, B.; Huizinga, J.; Pas, H.H.; Mulder, A.B.; Jonkman, M.F. Low-dose rituximab is effective in pemphigus. Br. J. Dermatol. 2012, 166, 405-412.
-
(2012)
Br. J. Dermatol
, vol.166
, pp. 405-412
-
-
Horváth, B.1
Huizinga, J.2
Pas, H.H.3
Mulder, A.B.4
Jonkman, M.F.5
-
26
-
-
84873712428
-
Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients
-
Leshem, Y.A.; Hodak, E.; David, M.; Anhalt, G.J.; Mimouni, D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients. J. Am. Acad. Dermatol. 2013, 68, 404-411.
-
(2013)
J. Am. Acad. Dermatol
, vol.68
, pp. 404-411
-
-
Leshem, Y.A.1
Hodak, E.2
David, M.3
Anhalt, G.J.4
Mimouni, D.5
-
27
-
-
84655164333
-
Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: A pilot study of 23 patients
-
Kasperkiewicz, M.; Shimanovich, I.; Meier, M.; Schumacher, N.; Westermann, L.; Kramer, J.; Zillikens, D.; Schmidt, E. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: A pilot study of 23 patients. Br. J. Dermatol. 2012, 166, 154-160.
-
(2012)
Br. J. Dermatol
, vol.166
, pp. 154-160
-
-
Kasperkiewicz, M.1
Shimanovich, I.2
Meier, M.3
Schumacher, N.4
Westermann, L.5
Kramer, J.6
Zillikens, D.7
Schmidt, E.8
-
28
-
-
24144491556
-
Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab
-
Jacobi, A.; Shuler, G.; Hertl, M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br. J. Dermatol. 2005, 153, 448-449.
-
(2005)
Br. J. Dermatol
, vol.153
, pp. 448-449
-
-
Jacobi, A.1
Shuler, G.2
Hertl, M.3
-
29
-
-
7744242111
-
Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept
-
Berookhim, B.; Fischer, H.D.; Weinberg, J.M. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004, 74, 245-247.
-
(2004)
Cutis
, vol.74
, pp. 245-247
-
-
Berookhim, B.1
Fischer, H.D.2
Weinberg, J.M.3
-
30
-
-
33845543681
-
Altered innate and adaptive immune responses in patients with hidradenitis suppurativa
-
Giamarellos-Bourboulis, E.J.; Antonopoulou, A.; Petropoulou, C.; Mouktaroudi, M.; Spyridaki, E.; Baziaka, F.; Pelekanou, A.; Giamarellou, H.; Stavrianeas, N.G. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br. J. Dermatol. 2007, 156, 51-56.
-
(2007)
Br. J. Dermatol
, vol.156
, pp. 51-56
-
-
Giamarellos-Bourboulis, E.J.1
Antonopoulou, A.2
Petropoulou, C.3
Mouktaroudi, M.4
Spyridaki, E.5
Baziaka, F.6
Pelekanou, A.7
Giamarellou, H.8
Stavrianeas, N.G.9
-
31
-
-
79957608446
-
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: A rationale for targeting TNF-α and IL-1β
-
Van der Zee, H.H.; de Ruiter, L.; van den Broecke, D.G.; Dik, W.A.; Laman, J.D.; Prens, E.P. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: A rationale for targeting TNF-α and IL-1β. Br. J. Dermatol. 2011, 164, 1292-1298.
-
(2011)
Br. J. Dermatol
, vol.164
, pp. 1292-1298
-
-
Van der Zee, H.H.1
de Ruiter, L.2
van den Broecke, D.G.3
Dik, W.A.4
Laman, J.D.5
Prens, E.P.6
-
32
-
-
84871353413
-
Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: A parallel randomized trial
-
Kimball, A.B.; Kerdel, F.; Adams, D.; Mrowietz, U.; Gelfand, J.M.; Gniadecki, R.; Prens, E.P.; Schlessinger, J.; Zouboulis, C.C.; van der Zee, H.H.; et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: A parallel randomized trial. Ann. Intern. Med. 2012, 157, 846-855.
-
(2012)
Ann. Intern. Med
, vol.157
, pp. 846-855
-
-
Kimball, A.B.1
Kerdel, F.2
Adams, D.3
Mrowietz, U.4
Gelfand, J.M.5
Gniadecki, R.6
Prens, E.P.7
Schlessinger, J.8
Zouboulis, C.C.9
van der Zee, H.H.10
-
33
-
-
84860904993
-
A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa
-
Sotiriou, E.; Goussi, C.; Lallas, A.; Chovarda, E.; Apalla, Z.; Lazaridou, E.; Ioannides, D. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J. Drugs Dermatol. 2012, 11(Suppl. 5), S15-S20.
-
(2012)
J. Drugs Dermatol
, vol.11
, Issue.5 SUPPL.
-
-
Sotiriou, E.1
Goussi, C.2
Lallas, A.3
Chovarda, E.4
Apalla, Z.5
Lazaridou, E.6
Ioannides, D.7
-
34
-
-
84871442684
-
The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: A systematic review
-
Van Rappard, D.C.; Limpens, J.; Mekkes, J.R. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: A systematic review. J. Dermatolog. Treat. 2012, 23, 22397574.
-
(2012)
J. Dermatolog. Treat
, vol.23
, pp. 22397574
-
-
van Rappard, D.C.1
Limpens, J.2
Mekkes, J.R.3
-
35
-
-
84863886830
-
Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa
-
Van Rappard, D.C.; Leenarts, M.F.; Meijerink-van't Oost, L.; Mekkes, J.R. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J. Dermatolog. Treat. 2012, 23, 284-289.
-
(2012)
J. Dermatolog. Treat
, vol.23
, pp. 284-289
-
-
van Rappard, D.C.1
Leenarts, M.F.2
Meijerink-Van't, O.L.3
Mekkes, J.R.4
-
36
-
-
80052789421
-
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
-
Schlapbach, C.; Hänni, T.; Yawalkar, N.; Hunger, R.E. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J. Am. Acad. Dermatol. 2011, 65, 790-798.
-
(2011)
J. Am. Acad. Dermatol
, vol.65
, pp. 790-798
-
-
Schlapbach, C.1
Hänni, T.2
Yawalkar, N.3
Hunger, R.E.4
-
37
-
-
84859738806
-
Management of recalcitrant hidradenitis suppurativa with ustekinumab
-
Sharon, V.R.; Garcia, M.S.; Bagheri, S.; Goodarzi, H.; Yang, C.; Ono, Y.; Maverakis, E. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta. Derm. Venereol. 2012, 92, 320-321.
-
(2012)
Acta. Derm. Venereol
, vol.92
, pp. 320-321
-
-
Sharon, V.R.1
Garcia, M.S.2
Bagheri, S.3
Goodarzi, H.4
Yang, C.5
Ono, Y.6
Maverakis, E.7
-
38
-
-
0028901436
-
Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression
-
Groves, R.W.; Allen, M.H.; Ross, E.L.; Barker, J.N.; MacDonald, D.M. Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br. J. Dermatol. 1995, 132, 345-352.
-
(1995)
Br. J. Dermatol
, vol.132
, pp. 345-352
-
-
Groves, R.W.1
Allen, M.H.2
Ross, E.L.3
Barker, J.N.4
Macdonald, D.M.5
-
39
-
-
84862164735
-
UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): Protocol for a randomised controlled trial
-
Craig, F.F.; Thomas, K.S.; Mitchell, E.J.; Williams, H.C.; Norrie, J.; Mason, J.M.; Ormerod, A.D. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): Protocol for a randomised controlled trial. Trials 2012, 13, 51.
-
(2012)
Trials
, vol.13
, pp. 51
-
-
Craig, F.F.1
Thomas, K.S.2
Mitchell, E.J.3
Williams, H.C.4
Norrie, J.5
Mason, J.M.6
Ormerod, A.D.7
-
40
-
-
23944510297
-
The effect of infliximab on extraintestinal manifestations of Crohn's disease
-
Kaufman, I.; Caspi, D.; Yeshurun, D.; Dotan, I.; Yaron, M.; Elkayam, O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol. Int. 2005, 25, 406-410.
-
(2005)
Rheumatol. Int
, vol.25
, pp. 406-410
-
-
Kaufman, I.1
Caspi, D.2
Yeshurun, D.3
Dotan, I.4
Yaron, M.5
Elkayam, O.6
-
41
-
-
84886749177
-
Six patients with pyoderma gangrenosum successfully treated with infliximab
-
doi:10.1111/j.1365-4632.2011.05201.x
-
Mooij, J.E.; van Rappard, D.C.; Mekkes, J.R. Six patients with pyoderma gangrenosum successfully treated with infliximab. Int. J. Dermatol. 2012, doi:10.1111/j.1365-4632.2011.05201.x.
-
(2012)
Int. J. Dermatol
-
-
Mooij, J.E.1
van Rappard, D.C.2
Mekkes, J.R.3
-
42
-
-
80054754826
-
Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab
-
Guenova, E.; Teske, A.; Fehrenbacher, B.; Hoerber, S.; Adamczyk, A.; Schaller, M.; Hoetzenecker, W.; Biedermann, T. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch. Dermatol. 2011, 147, 1203-1205.
-
(2011)
Arch. Dermatol
, vol.147
, pp. 1203-1205
-
-
Guenova, E.1
Teske, A.2
Fehrenbacher, B.3
Hoerber, S.4
Adamczyk, A.5
Schaller, M.6
Hoetzenecker, W.7
Biedermann, T.8
-
43
-
-
84869504616
-
International trends in the incidence of malignant melanoma 1953-2008-Are recent generations at higher or lower risk
-
Erdmann, F.; Lortet-Tieulent, J.; Schüz, J.; Zeeb, H.; Greinert, R.; Breitbart, E.W.; Bray, F. International trends in the incidence of malignant melanoma 1953-2008-Are recent generations at higher or lower risk? Int. J. Cancer 2013, 132, 385-400.
-
(2013)
Int. J. Cancer
, vol.132
, pp. 385-400
-
-
Erdmann, F.1
Lortet-Tieulent, J.2
Schüz, J.3
Zeeb, H.4
Greinert, R.5
Breitbart, E.W.6
Bray, F.7
-
44
-
-
84867313947
-
IFN-α in the treatment of melanoma
-
Tarhini, A.A.; Gogas, H.; Kirkwood, J.M. IFN-α in the treatment of melanoma. J. Immunol. 2012, 189, 3789-3793.
-
(2012)
J. Immunol
, vol.189
, pp. 3789-3793
-
-
Tarhini, A.A.1
Gogas, H.2
Kirkwood, J.M.3
-
45
-
-
1842533233
-
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
-
Kirkwood, J.M.; Manola, J.; Ibrahim, J.; Sondak, V.; Ernstoff, M.S.; Rao, U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 2004, 10, 1670-1677.
-
(2004)
Clin. Cancer Res
, vol.10
, pp. 1670-1677
-
-
Kirkwood, J.M.1
Manola, J.2
Ibrahim, J.3
Sondak, V.4
Ernstoff, M.S.5
Rao, U.6
-
46
-
-
84869212118
-
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma
-
Eggermont, A.M.; Suciu, S.; Testori, A.; Santinami, M.; Kruit, W.H.; Marsden, J.; Punt, C.J.; Salès, F.; Dummer, R.; Robert, C.; et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J. Clin. Oncol. 2012, 30, 3810-3818.
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 3810-3818
-
-
Eggermont, A.M.1
Suciu, S.2
Testori, A.3
Santinami, M.4
Kruit, W.H.5
Marsden, J.6
Punt, C.J.7
Salès, F.8
Dummer, R.9
Robert, C.10
-
47
-
-
0033024863
-
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
-
Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999, 17, 2105-2116.
-
(1999)
J. Clin. Oncol
, vol.17
, pp. 2105-2116
-
-
Atkins, M.B.1
Lotze, M.T.2
Dutcher, J.P.3
Fisher, R.I.4
Weiss, G.5
Margolin, K.6
Abrams, J.7
Sznol, M.8
Parkinson, D.9
Hawkins, M.10
-
48
-
-
55949125601
-
Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens
-
Dudley, M.E.; Yang, J.C.; Sherry, R.; Hughes, M.S.; Royal, R.; Kammula, U.; Robbins, P.F.; Huang, J.; Citrin, D.E.; Leitman, S.F.; et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26, 5233-5239.
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 5233-5239
-
-
Dudley, M.E.1
Yang, J.C.2
Sherry, R.3
Hughes, M.S.4
Royal, R.5
Kammula, U.6
Robbins, P.F.7
Huang, J.8
Citrin, D.E.9
Leitman, S.F.10
-
49
-
-
84865079230
-
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
-
Ellebaek, E.; Iversen, T.Z.; Junker, N.; Donia, M.; Engell-Noerregaard, L.; Met, O.; Hölmich, L.R.; Andersen, R.S.; Hadrup, S.R.; Andersen, M.H.; et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J. Transl. Med. 2012, 10, 169.
-
(2012)
J. Transl. Med
, vol.10
, pp. 169
-
-
Ellebaek, E.1
Iversen, T.Z.2
Junker, N.3
Donia, M.4
Engell-Noerregaard, L.5
Met, O.6
Hölmich, L.R.7
Andersen, R.S.8
Hadrup, S.R.9
Andersen, M.H.10
-
50
-
-
58749105795
-
Overcoming immunologic tolerance to melanoma: Targeting CTLA-4 with ipilimumab (MDX-010)
-
Weber, J. Overcoming immunologic tolerance to melanoma: Targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008, 13(Suppl. 4), 16-25.
-
(2008)
Oncologist
, vol.13
, Issue.4 SUPPL.
, pp. 16-25
-
-
Weber, J.1
-
51
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert, C.; Thomas, L.; Bondarenko, I.; O'Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl. J. Med. 2011, 364, 2517-2526.
-
(2011)
N Engl. J. Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
O'Day, S.4
Weber, J.5
Garbe, C.6
Lebbe, C.7
Baurain, J.F.8
Testori, A.9
Grob, J.J.10
-
52
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl. J. Med. 2010, 363, 711-723.
-
(2010)
N Engl. J. Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
-
53
-
-
84869212330
-
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
-
Ribas, A.; Chesney, J.A.; Gordon, M.S.; Abernethy, A.P.; Logan, T.F.; Lawson, D.H.; Chmielowksi, B.; Glaspy, J.A.; Lewis, K.; Huang, B.; et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J. Transl. Med. 2012, 10, 236.
-
(2012)
J. Transl. Med
, vol.10
, pp. 236
-
-
Ribas, A.1
Chesney, J.A.2
Gordon, M.S.3
Abernethy, A.P.4
Logan, T.F.5
Lawson, D.H.6
Chmielowksi, B.7
Glaspy, J.A.8
Lewis, K.9
Huang, B.10
-
54
-
-
76049092889
-
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma
-
Kirkwood, J.M.; Lorigan, P.; Hersey, P.; Hauschild, A.; Robert, C.; McDermott, D.; Marshall, M.A.; Gomez-Navarro, J.; Liang, J.Q.; Bulanhagui, C.A. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 2010, 16, 1042-1048.
-
(2010)
Clin. Cancer Res
, vol.16
, pp. 1042-1048
-
-
Kirkwood, J.M.1
Lorigan, P.2
Hersey, P.3
Hauschild, A.4
Robert, C.5
McDermott, D.6
Marshall, M.A.7
Gomez-Navarro, J.8
Liang, J.Q.9
Bulanhagui, C.A.10
-
55
-
-
61449090474
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma
-
Camacho, L.H.; Antonia, S.; Sosman, J.; Kirkwood, J.M.; Gajewski, T.F.; Redman, B.; Pavlov, D.; Bulanhagui, C.; Bozon, V.A.; Gomez-Navarro, J.; et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 2009, 27, 1075-1081.
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 1075-1081
-
-
Camacho, L.H.1
Antonia, S.2
Sosman, J.3
Kirkwood, J.M.4
Gajewski, T.F.5
Redman, B.6
Pavlov, D.7
Bulanhagui, C.8
Bozon, V.A.9
Gomez-Navarro, J.10
-
56
-
-
55949137090
-
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [oral]
-
Ribas, A.; Hauschild, A.; Kefford, R.; Punt, C.J.; Haanen, J.B.; Marmol, M.; Garbe, C.; Gomez-Navarro, J; Pavlov, D.; Marshall, M. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [oral]. J. Clin. Oncol. 2008, 20(Suppl. 15), LBA9011.
-
(2008)
J. Clin. Oncol
, vol.20
, Issue.15 SUPPL.
-
-
Ribas, A.1
Hauschild, A.2
Kefford, R.3
Punt, C.J.4
Haanen, J.B.5
Marmol, M.6
Garbe, C.7
Gomez-Navarro, J.8
Pavlov, D.9
Marshall, M.10
-
57
-
-
84868138286
-
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: Practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities
-
Sinha, R.; Edmonds, K.; Newton-Bishop, J.A.; Gore, M.E.; Larkin, J.; Fearfield, L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: Practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br. J. Dermatol. 2012, 167, 987-994.
-
(2012)
Br. J. Dermatol
, vol.167
, pp. 987-994
-
-
Sinha, R.1
Edmonds, K.2
Newton-Bishop, J.A.3
Gore, M.E.4
Larkin, J.5
Fearfield, L.6
-
58
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl. J. Med. 2011, 364, 2507-2516.
-
(2011)
N Engl. J. Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
Dummer, R.7
Garbe, C.8
Testori, A.9
Maio, M.10
-
59
-
-
84861745961
-
BRIM-1, -2 and -3 trials: Improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation
-
Young, K.; Minchom, A.; Larkin, J. BRIM-1, -2 and -3 trials: Improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol. 2012, 8, 499-507.
-
(2012)
Future Oncol
, vol.8
, pp. 499-507
-
-
Young, K.1
Minchom, A.2
Larkin, J.3
-
60
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild, A.; Grob, J.J.; Demidov, L.V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.U.; Miller, W.H., Jr.; Kaempgen, E.; et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380, 358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
Jouary, T.4
Gutzmer, R.5
Millward, M.6
Rutkowski, P.7
Blank, C.U.8
Miller Jr., W.H.9
Kaempgen, E.10
-
61
-
-
84868193136
-
Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma
-
Anforth, R.M.; Blumetti, T.C.; Kefford, R.F.; Sharma, R.; Scolyer, R.A.; Kossard, S.; Long, G.V.; Fernandez-Peñas, P. Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 2012, 167, 1153-1160.
-
(2012)
Br. J. Dermatol
, vol.167
, pp. 1153-1160
-
-
Anforth, R.M.1
Blumetti, T.C.2
Kefford, R.F.3
Sharma, R.4
Scolyer, R.A.5
Kossard, S.6
Long, G.V.7
Fernandez-Peñas, P.8
-
62
-
-
84874943389
-
BRAF inhibitor activity in V600R metastatic melanoma
-
Klein, O.; Clements, A.; Menzies, A.M.; O'Toole, S.; Kefford, R.F.; Long, G.V. BRAF inhibitor activity in V600R metastatic melanoma. Eur. J. Cancer 2013, 49, 1073-1079.
-
(2013)
Eur. J. Cancer
, vol.49
, pp. 1073-1079
-
-
Klein, O.1
Clements, A.2
Menzies, A.M.3
O'Toole, S.4
Kefford, R.F.5
Long, G.V.6
-
63
-
-
77949685981
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
-
Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464, 431-435.
-
(2010)
Nature
, vol.464
, pp. 431-435
-
-
Hatzivassiliou, G.1
Song, K.2
Yen, I.3
Brandhuber, B.J.4
Anderson, D.J.5
Alvarado, R.6
Ludlam, M.J.7
Stokoe, D.8
Gloor, S.L.9
Vigers, G.10
-
64
-
-
77949354563
-
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells
-
Halaban, R.; Zhang, W.; Bacchiocchi, A.; Cheng, E.; Parisi, F.; Ariyan, S.; Krauthammer, M.; McCusker, J.P.; Kluger, Y.; Sznol, M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment. Cell. Melanoma Res. 2010, 23, 190-200.
-
(2010)
Pigment. Cell. Melanoma Res
, vol.23
, pp. 190-200
-
-
Halaban, R.1
Zhang, W.2
Bacchiocchi, A.3
Cheng, E.4
Parisi, F.5
Ariyan, S.6
Krauthammer, M.7
McCusker, J.P.8
Kluger, Y.9
Sznol, M.10
-
65
-
-
84863673204
-
Improved survival with MEK inhibition in BRAF-mutated melanoma
-
Metric study group
-
Flaherty, K.T.; Robert, C.; Hersey, P.; Nathan, P.; Garbe, C.; Milhem, M.; Demidov, L.V.; Hassel, J.C.; Rutkowski, P.; Mohr, P. Metric study group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl. J. Med. 2012, 367, 107-114.
-
(2012)
N Engl. J. Med
, vol.367
, pp. 107-114
-
-
Flaherty, K.T.1
Robert, C.2
Hersey, P.3
Nathan, P.4
Garbe, C.5
Milhem, M.6
Demidov, L.V.7
Hassel, J.C.8
Rutkowski, P.9
Mohr, P.10
-
66
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty, K.T.; Infante, J.R.; Daud, A.; Gonzalez, R.; Kefford, R.F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl. J. Med. 2012, 367, 1694-1703.
-
(2012)
N Engl. J. Med
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
Gonzalez, R.4
Kefford, R.F.5
Sosman, J.6
Hamid, O.7
Schuchter, L.8
Cebon, J.9
Ibrahim, N.10
-
67
-
-
84858176826
-
Sorafenib in melanoma
-
Mangana, J.; Levesque, M.P.; Karpova, M.B.; Dummer, R. Sorafenib in melanoma. Expert Opin. Investig. Drugs 2012, 21, 557-568.
-
(2012)
Expert Opin. Investig. Drugs
, vol.21
, pp. 557-568
-
-
Mangana, J.1
Levesque, M.P.2
Karpova, M.B.3
Dummer, R.4
-
68
-
-
77954781214
-
Sorafenib: A clinical and pharmacologic review
-
Iyer, R.; Fetterly, G.; Lugade, A.; Thanavala, Y. Sorafenib: A clinical and pharmacologic review. Expert Opin. Pharmacother. 2010, 11, 1943-1955.
-
(2010)
Expert Opin. Pharmacother
, vol.11
, pp. 1943-1955
-
-
Iyer, R.1
Fetterly, G.2
Lugade, A.3
Thanavala, Y.4
-
69
-
-
67649909568
-
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
-
Hauschild, A.; Agarwala, S.S.; Trefzer, U.; Hogg, D.; Robert, C.; Hersey, P.; Eggermont, A.; Grabbe, S.; Gonzalez, R.; Gille, J.; et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 2009, 27, 2823-2830.
-
(2009)
J. Clin. Oncol
, vol.27
, pp. 2823-2830
-
-
Hauschild, A.1
Agarwala, S.S.2
Trefzer, U.3
Hogg, D.4
Robert, C.5
Hersey, P.6
Eggermont, A.7
Grabbe, S.8
Gonzalez, R.9
Gille, J.10
-
70
-
-
47049094020
-
Metastatic melanoma: Scientific rationale for sorafenib treatment and clinical results
-
Egberts, F.; Kahler, K.C.; Livingstone, E.; Hauschild, A. Metastatic melanoma: Scientific rationale for sorafenib treatment and clinical results. Onkologie 2008, 31, 398-403.
-
(2008)
Onkologie
, vol.31
, pp. 398-403
-
-
Egberts, F.1
Kahler, K.C.2
Livingstone, E.3
Hauschild, A.4
-
71
-
-
43749110700
-
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group
-
McDermott, D.F.; Sosman, J.A.; Gonzalez, R.; Hodi, F.S.; Linette, G.P.; Richards, J.; Jakub, J.W.; Beeram, M.; Tarantolo, S.; Agarwala, S.; et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. J. Clin. Oncol. 2008, 26, 2178-2185.
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 2178-2185
-
-
McDermott, D.F.1
Sosman, J.A.2
Gonzalez, R.3
Hodi, F.S.4
Linette, G.P.5
Richards, J.6
Jakub, J.W.7
Beeram, M.8
Tarantolo, S.9
Agarwala, S.10
-
72
-
-
73349121946
-
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
-
Amaravadi, R.K.; Schuchter, L.M.; McDermott, D.F.; Kramer, A.; Giles, L.; Gramlich, K.; Carberry, M.; Troxel, A.B.; Letrero, R.; Nathanson, K.L.; et al. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin. Cancer Res. 2009, 15, 7711-7718.
-
(2009)
Clin. Cancer Res
, vol.15
, pp. 7711-7718
-
-
Amaravadi, R.K.1
Schuchter, L.M.2
McDermott, D.F.3
Kramer, A.4
Giles, L.5
Gramlich, K.6
Carberry, M.7
Troxel, A.B.8
Letrero, R.9
Nathanson, K.L.10
-
73
-
-
84871961245
-
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
-
Ferguson, J.; Arozarena, I.; Ehrhardt, M.; Wellbrock, C. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene 2013, 32, 86-96.
-
(2013)
Oncogene
, vol.32
, pp. 86-96
-
-
Ferguson, J.1
Arozarena, I.2
Ehrhardt, M.3
Wellbrock, C.4
-
74
-
-
84876427625
-
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma
-
Gangadhar, T.C.; Clark, J.I.; Karrison, T.; Gajewski, T.F. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest. New Drugs 2012, 30, 23151808.
-
(1808)
Invest. New Drugs
, vol.30
, Issue.2315
, pp. 2012
-
-
Gangadhar, T.C.1
Clark, J.I.2
Karrison, T.3
Gajewski, T.F.4
-
75
-
-
0030005099
-
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
-
Agata, Y.; Kawasaki, A.; Nishimura, H.; Ishida, Y.; Tsubata, T.; Yagita, H.; Honjo, T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 1996, 8, 765-772.
-
(1996)
Int. Immunol
, vol.8
, pp. 765-772
-
-
Agata, Y.1
Kawasaki, A.2
Nishimura, H.3
Ishida, Y.4
Tsubata, T.5
Yagita, H.6
Honjo, T.7
-
76
-
-
42649125225
-
PD-1 and its ligands in tolerance and immunity
-
Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677-704.
-
(2008)
Annu. Rev. Immunol
, vol.26
, pp. 677-704
-
-
Keir, M.E.1
Butte, M.J.2
Freeman, G.J.3
Sharpe, A.H.4
-
77
-
-
33645863160
-
The PD-1-PD-L pathway in immunological tolerance
-
Okazaki, T.; Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006, 27, 195-201.
-
(2006)
Trends Immunol
, vol.27
, pp. 195-201
-
-
Okazaki, T.1
Honjo, T.2
-
78
-
-
77954899030
-
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
-
Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28, 3167-3175.
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
Powderly, J.D.4
Picus, J.5
Sharfman, W.H.6
Stankevich, E.7
Pons, A.8
Salay, T.M.9
McMiller, T.L.10
-
79
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl. J. Med. 2012, 366, 2455-2465.
-
(2012)
N Engl. J. Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
Drake, C.G.7
Camacho, L.H.8
Kauh, J.9
Odunsi, K.10
-
80
-
-
79959280523
-
Adaptive immune responses in primary cutaneous sarcoidosis
-
Bordignon, M.; Rottoli, P.; Agostini, C.; Alaibac, M. Adaptive immune responses in primary cutaneous sarcoidosis. Clin. Dev. Immunol. 2011, 2011, 235142.
-
(2011)
Clin. Dev. Immunol
, pp. 235142
-
-
Bordignon, M.1
Rottoli, P.2
Agostini, C.3
Alaibac, M.4
-
81
-
-
79251621675
-
Sarcoidosis is a Th1/Th17 multisystem disorder
-
Facco, M.; Cabrelle, A.; Teramo, A.; Olivieri, V.; Gnoato, M.; Teolato, S.; Ave, E.; Gattazzo, C.; Fadini, G.P.; Calabrese, F.; Semenzato, G.; Agostini, C. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011, 66, 144-150.
-
(2011)
Thorax
, vol.66
, pp. 144-150
-
-
Facco, M.1
Cabrelle, A.2
Teramo, A.3
Olivieri, V.4
Gnoato, M.5
Teolato, S.6
Ave, E.7
Gattazzo, C.8
Fadini, G.P.9
Calabrese, F.10
Semenzato, G.11
Agostini, C.12
-
82
-
-
0033009509
-
Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages
-
Marques, L.J.; Zheng, L.; Poulakis, N.; Guzman, J.; Costabel, U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am. J. Respir. Crit. Care Med. 1999, 159, 508-511.
-
(1999)
Am. J. Respir. Crit. Care Med
, vol.159
, pp. 508-511
-
-
Marques, L.J.1
Zheng, L.2
Poulakis, N.3
Guzman, J.4
Costabel, U.5
-
83
-
-
84871160440
-
A case series of refractory cutaneous sarcoidosis successfully treated with infliximab
-
Tuchinda, P.; Bremmer, M.; Gaspari, A.A. A case series of refractory cutaneous sarcoidosis successfully treated with infliximab. Dermatol. Ther. (Heidelb) 2012, 2, 11.
-
(2012)
Dermatol. Ther. (Heidelb)
, vol.2
, pp. 11
-
-
Tuchinda, P.1
Bremmer, M.2
Gaspari, A.A.3
-
84
-
-
84866495871
-
Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors
-
Wanat, K.A.; Rosenbach, M. Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. Arch. Dermatol. 2012, 148, 1097-1100.
-
(2012)
Arch. Dermatol
, vol.148
, pp. 1097-1100
-
-
Wanat, K.A.1
Rosenbach, M.2
-
85
-
-
84855859222
-
Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: Single-center retrospective study of 9 patients
-
Sené, T.; Juillard, C.; Rybojad, M.; Cordoliani, F.; Lebbé, C.; Morel, P.; Tazi, A.; Guibal, F. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: Single-center retrospective study of 9 patients. J. Am. Acad. Dermatol. 2012, 66, 328-332.
-
(2012)
J. Am. Acad. Dermatol
, vol.66
, pp. 328-332
-
-
Sené, T.1
Juillard, C.2
Rybojad, M.3
Cordoliani, F.4
Lebbé, C.5
Morel, P.6
Tazi, A.7
Guibal, F.8
-
86
-
-
33746460869
-
Etanercept for chronic progressive cutaneous sarcoidosis
-
Tuchinda, C.; Wong, H.K. Etanercept for chronic progressive cutaneous sarcoidosis. J. Drugs Dermatol. 2006, 5, 538-540.
-
(2006)
J. Drugs Dermatol
, vol.5
, pp. 538-540
-
-
Tuchinda, C.1
Wong, H.K.2
-
87
-
-
0042029539
-
Etanercept ameliorates sarcoidosis arthritis and skin disease
-
Khanna, D.; Liebling, M.R.; Louie, J.S. Etanercept ameliorates sarcoidosis arthritis and skin disease. J. Rheumatol. 2003, 30, 1864-1867.
-
(2003)
J. Rheumatol
, vol.30
, pp. 1864-1867
-
-
Khanna, D.1
Liebling, M.R.2
Louie, J.S.3
-
88
-
-
72149112252
-
Pityriasis rubra pilaris presenting with an abnormal autoimmune profile: Two case reports
-
Gregoriou, S.; Chiolou, Z.; Stefanaki, C.; Zakopoulou, N.; Rigopoulos, D.; Kontochristopoulos, G. Pityriasis rubra pilaris presenting with an abnormal autoimmune profile: Two case reports. J. Med. Case Rep. 2009, 3, 123.
-
(2009)
J. Med. Case Rep
, vol.3
, pp. 123
-
-
Gregoriou, S.1
Chiolou, Z.2
Stefanaki, C.3
Zakopoulou, N.4
Rigopoulos, D.5
Kontochristopoulos, G.6
-
89
-
-
0030775077
-
The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis
-
Magro, C.M.; Crowson, A.N. The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J. Cutan. Pathol. 1997, 24, 416-424.
-
(1997)
J. Cutan. Pathol
, vol.24
, pp. 416-424
-
-
Magro, C.M.1
Crowson, A.N.2
-
90
-
-
77955462690
-
Type I pityriasis rubra pilaris: Upregulation of tumor necrosis factor alpha and response to adalimumab therapy
-
Zhang, Y.H.; Zhou, Y.; Ball, N.; Su, M.W.; Xu, J.H.; Zheng, Z.Z. Type I pityriasis rubra pilaris: Upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J. Cutan. Med. Surg. 2010, 14, 185-188.
-
(2010)
J. Cutan. Med. Surg
, vol.14
, pp. 185-188
-
-
Zhang, Y.H.1
Zhou, Y.2
Ball, N.3
Su, M.W.4
Xu, J.H.5
Zheng, Z.Z.6
-
91
-
-
53349098835
-
Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy
-
Müller, H.; Gattringer, C.; Zelger, B.; Höpfl, R.; Eisendle, K. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy. J. Am. Acad. Dermatol. 2008, 59(Suppl. 5), S65-S70.
-
(2008)
J. Am. Acad. Dermatol
, vol.59
, Issue.5 SUPPL.
-
-
Müller, H.1
Gattringer, C.2
Zelger, B.3
Höpfl, R.4
Eisendle, K.5
-
92
-
-
77954398515
-
Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: A case series
-
Garcovich, S.; Di Giampetruzzi, A.R.; Antonelli, G.; Garcovich, A.; Didona, B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: A case series. J. Eur. Acad. Dermatol. Venereol. 2010, 24, 881-884.
-
(2010)
J. Eur. Acad. Dermatol. Venereol
, vol.24
, pp. 881-884
-
-
Garcovich, S.1
Di Giampetruzzi, A.R.2
Antonelli, G.3
Garcovich, A.4
Didona, B.5
-
93
-
-
77956921599
-
Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy
-
Ruiz Villaverde, R.; Sánchez Cano, D. Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur. J. Dermatol. 2010, 20, 630-631.
-
(2010)
Eur. J. Dermatol
, vol.20
, pp. 630-631
-
-
Ruiz Villaverde, R.1
Sánchez, C.D.2
-
94
-
-
77955891631
-
Treatment of pityriasis rubra pilaris with ustekinumab
-
Wohlrab, J.; Kreft, B. Treatment of pityriasis rubra pilaris with ustekinumab. Br. J. Dermatol. 2010, 163, 655-656.
-
(2010)
Br. J. Dermatol
, vol.163
, pp. 655-656
-
-
Wohlrab, J.1
Kreft, B.2
-
95
-
-
0026603797
-
Profile of alopecia areata: A questionnaire analysis of patient and family
-
Shellow, W.V.; Edwards, J.E.; Koo, J.Y. Profile of alopecia areata: A questionnaire analysis of patient and family. Int. J. Dermatol. 1992, 31, 186-189.
-
(1992)
Int. J. Dermatol
, vol.31
, pp. 186-189
-
-
Shellow, W.V.1
Edwards, J.E.2
Koo, J.Y.3
-
96
-
-
0023229384
-
Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: Modulation by topical immunotherapy
-
Bröcker, E.B.; Echternacht-Happle, K.; Hamm, H.; Happle, R. Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: Modulation by topical immunotherapy. J. Invest. Dermatol. 1987, 88, 564-568.
-
(1987)
J. Invest. Dermatol
, vol.88
, pp. 564-568
-
-
Bröcker, E.B.1
Echternacht-Happle, K.2
Hamm, H.3
Happle, R.4
-
97
-
-
0027436068
-
HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: The role of cytokines
-
Mcdonagh, A.J.; Snowden, J.A.; Stierle, C.; Elliott, K.; Messenger, A.G. HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: The role of cytokines. Br. J. Dermatol. 1993, 129, 250-256.
-
(1993)
Br. J. Dermatol
, vol.129
, pp. 250-256
-
-
McDonagh, A.J.1
Snowden, J.A.2
Stierle, C.3
Elliott, K.4
Messenger, A.G.5
-
98
-
-
0036911686
-
Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4+ and CD8+ cells
-
McElwee, K.J.; Hoffmann, R.; Freyschmidt-Paul, P.; Wenzel, E.; Kissling, S.; Sundberg, J.P.; Zöller, M. Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4+ and CD8+ cells. J. Invest. Dermatol. 2002, 119, 1426-1433.
-
(2002)
J. Invest. Dermatol
, vol.119
, pp. 1426-1433
-
-
McElwee, K.J.1
Hoffmann, R.2
Freyschmidt-Paul, P.3
Wenzel, E.4
Kissling, S.5
Sundberg, J.P.6
Zöller, M.7
-
99
-
-
79954628956
-
Alopecia areata during anti-TNF alpha therapy: Nine cases
-
Le Bidre, E.; Chaby, G.; Martin, L.; Perrussel, M.; Sassolas, B.; Sigal, M.L.; Kaassis, C.; Lespessailles, E.; Nseir, A.; Estève, E. Alopecia areata during anti-TNF alpha therapy: Nine cases. Ann. Dermatol. Venereol. 2011, 138, 285-293.
-
(2011)
Ann. Dermatol. Venereol
, vol.138
, pp. 285-293
-
-
Le Bidre, E.1
Chaby, G.2
Martin, L.3
Perrussel, M.4
Sassolas, B.5
Sigal, M.L.6
Kaassis, C.7
Lespessailles, E.8
Nseir, A.9
Estève, E.10
-
100
-
-
29144523203
-
Alefacept for alopecia areata
-
Heffernan, M.P.; Hurley, M.Y.; Martin, K.S.; Smith, D.I.; Anadkat, M.J. Alefacept for alopecia areata. Arch. Dermatol. 2005, 141, 1513-1516.
-
(2005)
Arch. Dermatol
, vol.141
, pp. 1513-1516
-
-
Heffernan, M.P.1
Hurley, M.Y.2
Martin, K.S.3
Smith, D.I.4
Anadkat, M.J.5
-
101
-
-
72749106793
-
Alefacept for severe alopecia areata: A randomized, double-blind, placebo-controlled study
-
Strober, B.E.; Menon, K.; McMichael, A.; Hordinsky, M.; Krueger, G.; Panko, J.; Siu, K.; Lustgarten, J.L.; Ross, E.K.; Shapiro, J. Alefacept for severe alopecia areata: A randomized, double-blind, placebo-controlled study. Arch. Dermatol. 2009, 145, 1262-1266.
-
(2009)
Arch. Dermatol
, vol.145
, pp. 1262-1266
-
-
Strober, B.E.1
Menon, K.2
McMichael, A.3
Hordinsky, M.4
Krueger, G.5
Panko, J.6
Siu, K.7
Lustgarten, J.L.8
Ross, E.K.9
Shapiro, J.10
-
102
-
-
33746874475
-
Treatment of alopecia areata partim universalis with efalizumab
-
Kaelin, U.; Hassan, A.S.; Braathen, L.R.; Yawalkar, N. Treatment of alopecia areata partim universalis with efalizumab. J. Am. Acad. Dermatol. 2006, 55, 529-532.
-
(2006)
J. Am. Acad. Dermatol
, vol.55
, pp. 529-532
-
-
Kaelin, U.1
Hassan, A.S.2
Braathen, L.R.3
Yawalkar, N.4
-
103
-
-
56549118393
-
Successful treatment of alopecia areata with efalizumab
-
Kolde, G.; Meffert, H.; Rowe, E. Successful treatment of alopecia areata with efalizumab. J. Eur. Acad. Dermatol. Venereol. 2008, 22, 1519-1520.
-
(2008)
J. Eur. Acad. Dermatol. Venereol
, vol.22
, pp. 1519-1520
-
-
Kolde, G.1
Meffert, H.2
Rowe, E.3
-
104
-
-
38949195709
-
Subcutaneous efalizumab is not effective in the treatment of alopecia areata
-
Price, V.H.; Hordinsky, M.K.; Olsen, E.A.; Roberts, J.L.; Siegfried, E.C.; Rafal, E.S.; Korman, N.J.; Altrabulsi, B.; Leung, H.M.; Garovoy, M.R.; et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J. Am. Acad. Dermatol. 2008, 58, 395-402.
-
(2008)
J. Am. Acad. Dermatol
, vol.58
, pp. 395-402
-
-
Price, V.H.1
Hordinsky, M.K.2
Olsen, E.A.3
Roberts, J.L.4
Siegfried, E.C.5
Rafal, E.S.6
Korman, N.J.7
Altrabulsi, B.8
Leung, H.M.9
Garovoy, M.R.10
-
105
-
-
84860455427
-
Chronic urticaria and autoimmunity: Associations found in a large population study
-
Confino-Cohen, R.; Chodick, G.; Shalev, V.; Leshno, M.; Kimhi, O.; Goldberg, A. Chronic urticaria and autoimmunity: Associations found in a large population study. J. Allergy Clin. Immunol. 2012, 129, 1307-1313.
-
(2012)
J. Allergy Clin. Immunol
, vol.129
, pp. 1307-1313
-
-
Confino-Cohen, R.1
Chodick, G.2
Shalev, V.3
Leshno, M.4
Kimhi, O.5
Goldberg, A.6
-
106
-
-
84869824587
-
Treatment of chronic spontaneous urticaria
-
Kaplan, A.P. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol. Res. 2012, 4, 326-331.
-
(2012)
Allergy Asthma Immunol. Res
, vol.4
, pp. 326-331
-
-
Kaplan, A.P.1
-
107
-
-
50649084564
-
Treatment of chronic autoimmune urticaria with omalizumab
-
Kaplan, A.P.; Joseph, K.; Maykut, R.J.; Geba, G.P.; Zeldin, R.K. Treatment of chronic autoimmune urticaria with omalizumab. J. Allergy Clin. Immunol. 2008, 122, 569-573.
-
(2008)
J. Allergy Clin. Immunol
, vol.122
, pp. 569-573
-
-
Kaplan, A.P.1
Joseph, K.2
Maykut, R.J.3
Geba, G.P.4
Zeldin, R.K.5
-
108
-
-
80052299857
-
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria
-
Saini, S.; Rosen, K.E.; Hsieh, H.J.; Wong, D.A.; Conner, E.; Kaplan, A.; Spector, S.; Maurer, M. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2011, 128, 567-573.
-
(2011)
J. Allergy Clin. Immunol
, vol.128
, pp. 567-573
-
-
Saini, S.1
Rosen, K.E.2
Hsieh, H.J.3
Wong, D.A.4
Conner, E.5
Kaplan, A.6
Spector, S.7
Maurer, M.8
-
109
-
-
79955575746
-
Omalizumab is effective in nonautoimmune urticaria
-
Ferrer, M.; Gamboa, P.; Sanz, M.L.; Goikoetxea, M.J.; Cabrera-Freitag, P.; Javaloyes, G.; Berroa, F.; Kaplan, A.P. Omalizumab is effective in nonautoimmune urticaria. J. Allergy Clin. Immunol. 2011, 127, 1300-1302.
-
(2011)
J. Allergy Clin. Immunol
, vol.127
, pp. 1300-1302
-
-
Ferrer, M.1
Gamboa, P.2
Sanz, M.L.3
Goikoetxea, M.J.4
Cabrera-Freitag, P.5
Javaloyes, G.6
Berroa, F.7
Kaplan, A.P.8
-
110
-
-
84860776801
-
Omalizumab for chronic urticaria: A case series and overview of the literature
-
Ivyanskiy, I.; Sand, C.; Thomsen, S.F. Omalizumab for chronic urticaria: A case series and overview of the literature. Case Rep. Dermatol. 2012, 4, 19-26.
-
(2012)
Case Rep. Dermatol
, vol.4
, pp. 19-26
-
-
Ivyanskiy, I.1
Sand, C.2
Thomsen, S.F.3
-
112
-
-
53949103784
-
Possible pathogenic role of Th17 cells for atopic dermatitis
-
Koga, C.; Kabashima, K.; Shiraishi, N.; Kobayashi, M.; Tokura, Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J. Invest. Dermatol. 2008, 128, 2625-2630.
-
(2008)
J. Invest. Dermatol
, vol.128
, pp. 2625-2630
-
-
Koga, C.1
Kabashima, K.2
Shiraishi, N.3
Kobayashi, M.4
Tokura, Y.5
-
113
-
-
0027500014
-
Recombinant interferon gamma therapy for atopic dermatitis
-
Hanifin, J.M.; Schneider, L.C.; Leung, D.Y.; Ellis, C.N.; Jaffe, H.S.; Izu, A.E.; Bucalo, L.R.; Hirabayashi, S.E.; Tofte, S.J.; Cantu-Gonzales, G.; et al. Recombinant interferon gamma therapy for atopic dermatitis. J. Am. Acad. Dermatol. 1993, 28, 189-197.
-
(1993)
J. Am. Acad. Dermatol
, vol.28
, pp. 189-197
-
-
Hanifin, J.M.1
Schneider, L.C.2
Leung, D.Y.3
Ellis, C.N.4
Jaffe, H.S.5
Izu, A.E.6
Bucalo, L.R.7
Hirabayashi, S.E.8
Tofte, S.J.9
Cantu-Gonzales, G.10
-
114
-
-
0031941774
-
Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis
-
Schneider, L.C.; Baz, Z.; Zarcone, C.; Zurakowski, D. Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann. Allergy Asthma Immunol. 1998, 80, 263-268.
-
(1998)
Ann. Allergy Asthma Immunol
, vol.80
, pp. 263-268
-
-
Schneider, L.C.1
Baz, Z.2
Zarcone, C.3
Zurakowski, D.4
-
115
-
-
0034129549
-
Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma
-
Jang, I.G.; Yang, J.K.; Lee, H.J.; Yi, J.Y.; Kim, H.O.; Kim, C.W.; Kim, T.Y. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J. Am. Acad. Dermatol. 2000, 42, 1033-1040.
-
(2000)
J. Am. Acad. Dermatol
, vol.42
, pp. 1033-1040
-
-
Jang, I.G.1
Yang, J.K.2
Lee, H.J.3
Yi, J.Y.4
Kim, H.O.5
Kim, C.W.6
Kim, T.Y.7
-
116
-
-
0028153546
-
Interferon therapy for atopic dermatitis reduces basophil histamine release, but does not reduce serum IgE or eosinophilic proteins
-
Nielsen, B.W.; Reimert, C.M.; Hammer, R.; Schiøtz, P.O.; Thestrup-Pedersen, K. Interferon therapy for atopic dermatitis reduces basophil histamine release, but does not reduce serum IgE or eosinophilic proteins. Allergy 1994, 49, 120-128.
-
(1994)
Allergy
, vol.49
, pp. 120-128
-
-
Nielsen, B.W.1
Reimert, C.M.2
Hammer, R.3
Schiøtz, P.O.4
Thestrup-Pedersen, K.5
-
117
-
-
0027166746
-
Alpha interferon treatment in atopic dermatitis
-
Jullien, D.; Nicolas, J.F.; Frappaz, A.; Thivolet, J. Alpha interferon treatment in atopic dermatitis. Acta. Derm. Venereol. 1993, 73, 130-132.
-
(1993)
Acta. Derm. Venereol
, vol.73
, pp. 130-132
-
-
Jullien, D.1
Nicolas, J.F.2
Frappaz, A.3
Thivolet, J.4
-
118
-
-
0032432952
-
Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis
-
Noh, G.W.; Lee, K.Y. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 1998, 53, 1202-1207.
-
(1998)
Allergy
, vol.53
, pp. 1202-1207
-
-
Noh, G.W.1
Lee, K.Y.2
-
119
-
-
0034099363
-
The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: A report of three patients and review of the literature
-
Jolles, S.; Hughes, J.; Rustin, M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: A report of three patients and review of the literature. Br. J. Dermatol. 2000, 142, 551-554.
-
(2000)
Br. J. Dermatol
, vol.142
, pp. 551-554
-
-
Jolles, S.1
Hughes, J.2
Rustin, M.3
-
120
-
-
0345258012
-
Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: Efficacy and effects on intracellular cytokine levels and CD4 counts
-
Jolles, S.; Sewell, C.; Webster, D.; Ryan, A.; Heelan, B.; Waite, A.; Rustin, M. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: Efficacy and effects on intracellular cytokine levels and CD4 counts. Acta. Derm. Venereol. 2003, 83, 433-437.
-
(2003)
Acta. Derm. Venereol
, vol.83
, pp. 433-437
-
-
Jolles, S.1
Sewell, C.2
Webster, D.3
Ryan, A.4
Heelan, B.5
Waite, A.6
Rustin, M.7
-
121
-
-
0036047753
-
A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis
-
Paul, C.; Lahfa, M.; Bachelez, H.; Chevret, S.; Dubertret, L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br. J. Dermatol. 2002, 147, 518-522.
-
(2002)
Br. J. Dermatol
, vol.147
, pp. 518-522
-
-
Paul, C.1
Lahfa, M.2
Bachelez, H.3
Chevret, S.4
Dubertret, L.5
-
122
-
-
55449114921
-
High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis
-
Bemanian, M.H.; Movahedi, M.; Farhoudi, A.; Gharagozlou, M.; Seraj, M.H.; Pourpak, Z.; Nabavi, M.; Aghamohammadi, A.; Shirkhoda, Z. High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. Iran. J. Allergy Asthma Immunol. 2005, 4, 139-143.
-
(2005)
Iran. J. Allergy Asthma Immunol
, vol.4
, pp. 139-143
-
-
Bemanian, M.H.1
Movahedi, M.2
Farhoudi, A.3
Gharagozlou, M.4
Seraj, M.H.5
Pourpak, Z.6
Nabavi, M.7
Aghamohammadi, A.8
Shirkhoda, Z.9
-
123
-
-
43249130077
-
Alefacept for moderate to severe atopic dermatitis: A pilot study in adults
-
Moul, D.K.; Routhouska, S.B.; Robinson, M.R.; Korman, N.J. Alefacept for moderate to severe atopic dermatitis: A pilot study in adults. J. Am. Acad. Dermatol. 2008, 58, 984-989.
-
(2008)
J. Am. Acad. Dermatol
, vol.58
, pp. 984-989
-
-
Moul, D.K.1
Routhouska, S.B.2
Robinson, M.R.3
Korman, N.J.4
-
124
-
-
33846038623
-
Efalizumab for severe atopic dermatitis: A pilot study in adults
-
Takiguchi, R.; Tofte, S.; Simpson, B.; Harper, E.; Blauvelt, A.; Hanifin, J.; Simpson, E. Efalizumab for severe atopic dermatitis: A pilot study in adults. J. Am. Acad. Dermatol. 2007, 56, 222-227.
-
(2007)
J. Am. Acad. Dermatol
, vol.56
, pp. 222-227
-
-
Takiguchi, R.1
Tofte, S.2
Simpson, B.3
Harper, E.4
Blauvelt, A.5
Hanifin, J.6
Simpson, E.7
-
125
-
-
38149055540
-
Anti-CD20 (rituximab) treatment improves atopic eczema
-
Simon, D.; Hösli, S.; Kostylina, G.; Yawalkar, N.; Simon, H.U. Anti-CD20 (rituximab) treatment improves atopic eczema. J. Allergy Clin. Immunol. 2008, 121, 122-128.
-
(2008)
J. Allergy Clin. Immunol
, vol.121
, pp. 122-128
-
-
Simon, D.1
Hösli, S.2
Kostylina, G.3
Yawalkar, N.4
Simon, H.U.5
-
126
-
-
54049087804
-
Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study
-
Sheinkopf, L.E.; Rafi, A.W.; Do, L.T.; Katz, R.M.; Klaustermeyer, W.B. Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study. Allergy Asthma Proc. 2008, 29, 530-537.
-
(2008)
Allergy Asthma Proc
, vol.29
, pp. 530-537
-
-
Sheinkopf, L.E.1
Rafi, A.W.2
Do, L.T.3
Katz, R.M.4
Klaustermeyer, W.B.5
-
127
-
-
2942560685
-
Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin
-
Phipps, S.; Flood-Page, P.; Menzies-Gow, A.; Ong, Y.E.; Kay, A.B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J. Invest. Dermatol. 2004, 122, 1406-1412.
-
(2004)
J. Invest. Dermatol
, vol.122
, pp. 1406-1412
-
-
Phipps, S.1
Flood-Page, P.2
Menzies-Gow, A.3
Ong, Y.E.4
Kay, A.B.5
-
128
-
-
70349314513
-
Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy
-
Rullan, P.; Murase, J. Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy. J. Drugs Dermatol. 2009, 8, 873-876.
-
(2009)
J. Drugs Dermatol
, vol.8
, pp. 873-876
-
-
Rullan, P.1
Murase, J.2
-
129
-
-
24944536778
-
Infliximab in the treatment of moderate to severe atopic dermatitis
-
Jacobi, A.; Antoni, C.; Manger, B.; Schuler, G.; Hertl, M. Infliximab in the treatment of moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 2005, 52, 522-526.
-
(2005)
J. Am. Acad. Dermatol
, vol.52
, pp. 522-526
-
-
Jacobi, A.1
Antoni, C.2
Manger, B.3
Schuler, G.4
Hertl, M.5
|